InvVax is pioneering the development of the world's first universal influenza vaccine, revolutionizing the way we protect against the flu. By meticulously mapping the entire flu genome, founder Arthur Young identified 15 regions of the virus that cannot mutate without self-destructing, leading to the creation of a unique vaccine that specifically targets these invariant positions. Unlike traditional vaccines that only focus on conserved regions, InvVax addresses both the strain mismatch and mutation issues, offering a comprehensive solution to flu prevention.

With patent-pending technology and a strategic partnership with Wilson Sonsini, we are at the forefront of vaccine innovation. Join us in changing the world with our groundbreaking approach to influenza protection. Stay updated by signing up for our newsletter and reach out to us at Pasadena Bioscience Collaborative for more information.

Protect. Prevent. Innovate with InvVax